Capecitabine + Sunitinib
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Breast Cancer
Conditions
Advanced/Metastatic Breast Cancer
Trial Timeline
Apr 1, 2008 → May 1, 2012
NCT ID
NCT00662025About Capecitabine + Sunitinib
Capecitabine + Sunitinib is a phase 2 stage product being developed by Pfizer for Advanced/Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00662025. Target conditions include Advanced/Metastatic Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00662025 | Phase 2 | Completed |
Competing Products
20 competing products in Advanced/Metastatic Breast Cancer